-The Times of India NEW DELHI: In an attempt to ease norms for testing and introduction of new medicines in the country, the government has taken steps to fast-track approvals for clinical trials as well as launch of drugs already approved in other countries. Pharmaceutical companies planning to launch new drugs already approved outside India after conducting pre-clinical or toxicological studies on animals will not be required to repeat such studies in...

-The Times of India LUCKNOW: A scientifically validated anti-diabetes herbal drug, named 'BGR-34', was launched by a Council of Scientific and Industrial Research (CSIR) lab in Lucknow on Sunday. A combination of natural extracts from plants, the drug is based on Ayurveda and has no side effects. The drug is for management of type-II diabetes mellitus. The drug has been jointly developed by two CSIR laboratories, National Botanical Research Institute (NBRI) and...

-The Times of India MUMBAI: Certain medicines are being aggressively marketed in India despite inadequate evidence of safety and efficacy, putting patients at risk, said reputed medical journal Lancet. Highlighting weak regulation and monitoring of the domestic drug industry, three recently-introduced medicines are being prescribed and sold though there is a lack of rigorous trials on crucial safety and efficacy parameters. The pharmaceutical industry in India should face the same stringent regulations...

-The Hindu Business Line Transparency required on data concerning clinical trials and procurement of drugs Earlier this year, rotavirus vaccine 116E was launched with much fanfare. The celebration of this vaccine that would protect infants against rotavirus gastroenteritis was on two counts. It was developed locally and its price was pegged at $1, less than competing rotavirus vaccines that sell in the country. But the rollout of this indigenous vaccine as part of...

-Economic and Political Weekly The health ministry's move on HPV vaccine feasibility is ill-advised. The union health ministry has asked the National Technical Advisory Group on Immunisation (NTAGI) to examine the feasibility of introducing the Human Papillomavirus (HPV) vaccine in the country’s universal immunisation programme. The NTAGI has been given three months for this task. The HPV vaccine, which is supposed to protect against cervical cancer in girls and women, is generally...